Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 9,999 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,999 shares of the stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $80.60, for a total value of $805,919.40. Following the completion of the sale, the senior vice president owned 14,219 shares in the company, valued at approximately $1,146,051.40. The trade was a 41.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, September 21st, Arjun Agarwal sold 533 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.75, for a total value of $51,034.75.
• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.71, for a total value of $53,597.60.
• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.23, for a total value of $872,403.57.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00.

Oruka Therapeutics Stock Performance

ORKA stock traded down $2.16 during midday trading on Tuesday, reaching $78.19. The company’s stock had a trading volume of 490,798 shares, compared to its average volume of 1,091,331. Oruka Therapeutics, Inc. has a 1 year low of $24.88 and a 1 year high of $115.51. The firm has a market capitalization of $5.18 billion, a price-to-earnings ratio of -38.52 and a beta of -0.37. The stock has a fifty day simple moving average of $94.29 and a two-hundred day simple moving average of $79.41.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, analysts forecast that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ORKA shares. Wedbush set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 24th. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. BTIG Research reaffirmed a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. UBS Group boosted their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, Piper Sandler reissued an “overweight” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Oruka Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $128.91.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ORKA. GAMMA Investing LLC raised its stake in Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after buying an additional 250 shares in the last quarter. Engineers Gate Manager LP purchased a new stake in Oruka Therapeutics during the second quarter worth $350,000. Arizona State Retirement System lifted its holdings in Oruka Therapeutics by 45.0% during the second quarter. Arizona State Retirement System now owns 8,671 shares of the company’s stock worth $825,000 after buying an additional 2,691 shares during the period. Nykredit A S bought a new stake in Oruka Therapeutics during the 2nd quarter valued at $29,000. Finally, Braidwell LP bought a new stake in Oruka Therapeutics during the 2nd quarter valued at $26,473,000. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.